Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc. (NASDAQ:AVTX), sold shares of the company’s common stock and acquired shares through the exercise of stock options on August 17, 2026, according to a recent SEC Form 4 filing. These transactions were executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Doyle on November 13, 2025.

The Chief Medical Officer sold 1,000 shares of Avalo Therapeutics common stock at a price of $20.00 per share, totaling $20,000. The sale comes as the stock has delivered an 83% return over the past year, though InvestingPro analysis suggests the stock may be overvalued at current levels, with shares trading at $19.34, near their 52-week high of $24.27.

Concurrently, Doyle acquired 1,000 shares of common stock by exercising stock options at an exercise price of $12.65 per share, amounting to a total value of $12,650 for the acquisition. The stock option exercised was part of a grant that vests twenty-five percent on July 15, 2025, with the remainder vesting in equal monthly installments over the subsequent three years, contingent on continued service.

Following these transactions, Mittie Doyle directly owns 51,776 shares of Avalo Therapeutics common stock. Additionally, Doyle holds 123,750 derivative securities in the form of stock options.

In other recent news, Avalo Therapeutics announced its addition to the Russell 2000 and 3000 indexes, reflecting its status among the largest publicly traded U.S. companies. This move is significant as the Russell 2000 Index serves as a benchmark for U.S. small-cap equities. Avalo Therapeutics also appointed Ron Philip to its board of directors, where he will serve on the Compensation Committee and the Science, Development and Commercial Advisory Committee. Philip brings over 30 years of biopharmaceutical experience, having previously led Orbital Therapeutics through a major acquisition by Bristol Myers Squibb.

In analyst updates, Cantor Fitzgerald reiterated an Overweight rating on Avalo Therapeutics, focusing on the company’s abdakibart (IL-1b) Phase 2 data for hidradenitis suppurativa. Leerink initiated coverage on Avalo with an Outperform rating and set a price target of $38.00. These developments highlight the company’s progress in developing IL-1β-based therapies for immune-mediated inflammatory diseases. Avalo’s lead program, abdakibart (AVTX-009), has shown positive Phase 2 results, which are being closely monitored by analysts.